Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates

Company Performance - Kiniksa Pharmaceuticals reported a quarterly loss of $0.06 per share, better than the Zacks Consensus Estimate of a loss of $0.09, compared to a loss of $0.02 per share a year ago [1] - The company posted revenues of $108.63 million for the quarter, surpassing the Zacks Consensus Estimate by 23.68%, and compared to year-ago revenues of $71.47 million [11] - Over the last four quarters, Kiniksa has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2][11] Market Comparison - Kiniksa Pharmaceuticals shares have increased by approximately 22% since the beginning of the year, outperforming the S&P 500's gain of 16.7% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $99.65 million, and -$0.10 on revenues of $380.84 million for the current fiscal year [5] - The company is expected to post a quarterly loss of $0.42 per share in its upcoming report, reflecting a year-over-year change of -16.7% [6] Estimate Revisions - The estimate revisions trend for Kiniksa Pharmaceuticals is mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [9] Industry Context - Kiniksa Pharmaceuticals operates within the Zacks Medical - Biomedical and Genetics industry, which is currently in the top 33% of over 250 Zacks industries [14]